TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04975438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study: NCT06577155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Regional anesthesia / analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine plus nalbuphine
Description: Regional anesthesia / analgesia
Study: NCT05623878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-labeled NY108
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.
Study: NCT04959877

Intervention type: BEHAVIORAL
Intervention: health education
Description: data collect / Telemedicine
Study: NCT05464342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening LGI Carbohydrate Consumption Group
Description: Participants will receive in the evening food with low glycemic index

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening HGI Carbohydrate Consumption
Description: Participants will receive in the evening food with high glycemic index

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening NO-CHO Carbohydrate Consumption
Description: Participants will receive in the evening a meal with no carbohydrates at all.
Study: NCT06044779

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block using 0.25% Bupivacaine
Description: TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block using 0.25% Bupivacaine
Description: Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
Study: NCT05862077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Hip Assist Robot(EX1)
Description: EX1 is a hip-type assist device developed by Samsung Electronics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Hip Assist Robot(EX1)
Description: EX1 is a hip-type assist device developed by Samsung Electronics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program 1
Description: Exercise program 1 for fast walking by applying resistance and assist mode of EX1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program 2
Description: Exercise program 2 for normal walking by applying resistance and assist mode of EX1

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Without Wearable Hip Assist Robot(EX1)
Description: Overground walking without EX1
Study: NCT04883008

Intervention type: DEVICE
Intervention: CorPath GRX with technIQ automated movements enabled (technIQ ON)
Description: The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist.

Intervention type: DEVICE
Intervention: CorPath GRX with technIQ automated movements disabled (technIQ OFF).
Description: The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled.
Study: NCT04982146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelin
Description: 0.5mg per mL of total tumor volume calculated, administered percutaneously
Study: NCT04634656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
Study: NCT05999968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist/antagonist
Description: Physician's choice. Administered in accordance with the prescribing information.
Study: NCT04845282

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Graded Protein plus Resistance Training
Description: Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RDA Protein plus Resistance Training
Description: Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
Study: NCT06027164

Intervention type: DEVICE
Intervention: Portable Ultrasound System
Description: EchoNous KOSMOS
Study: NCT04588038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efineptakin alfa
Description: Given via intramuscular injection
Study: NCT04985123

Intervention type: DEVICE
Intervention: Pre-Formed Penile Silicone Block Implant
Description: Implantation of Pre-Formed Penile Silicone Block Implant
Study: NCT06193460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: photobiomodulation mode of diode laser (low-level laser therapy).
Study: NCT05535465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Public health intervention
Description: additional trained mobile health workers are hired to support and supervise the activities of community health workers
Study: NCT05602831

Intervention type: OTHER
Intervention: detect HPV and genetic variants
Description: Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline surgical tissues.

Intervention type: OTHER
Intervention: detect HPV and genetic variants
Description: Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline puncture tissues.
Study: NCT05849948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choronobiological nutrition
Description: Providing infant nutrition in accordance with crinobiological nutrition
Study: NCT05516550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid
Description: Participants will receive Treamid 25 mg once a day daily during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid twice a day
Description: Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid once a day
Description: Participants will receive Treamid 50 mg in the morning daily during 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo in the morning and in the evening daily during 4 weeks
Study: NCT03503032

Intervention type: PROCEDURE
Intervention: Extracardiac Fontan
Description: Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery \[applied to both arms\]

Intervention type: PROCEDURE
Intervention: Extracardiac Fontan
Description: Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery \[applied to both arms\]

Intervention type: PROCEDURE
Intervention: Fontan fenestration
Description: Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium \[Fenestrated arm\]
Study: NCT06473129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food for Life Culinary Workshops
Description: Whole food, plant based 2hr workshop, which includes background information on diabetes, how to shop for food, etc and then a culinary demonstration and tasting of whole food, plant based dishes.
Study: NCT05172349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LV-Visio-AMTRIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
Study: NCT04684277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antidepressant treatment
Description: depression recieve antidepressant treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antidepressant treatment combined with Internet-based interventions
Description: depression recieve antidepressant treatment combined with Internet-based interventions
Study: NCT05486377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Remimazolam besylate TIVA
Study: NCT05673967

Intervention type: OTHER
Intervention: Non-Interventional
Description: No study treatment will be administered on this study.
Study: NCT04986904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi (Sleep Healthy Using the Internet)
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
Study: NCT05294549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caring Contact
Description: The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
Study: NCT06498076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: injection of prophylactic norepinephrinebolus after spinal anesthesia induction. If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: injection of prophylactic ephedrine If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
Study: NCT01687530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMCA Bone Membrane.
Description: AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
Study: NCT05634525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: Given By PO
Study: NCT06335043

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetics Testing
Description: Genetic test to determine individual genetic compatibility with multiple pharmaceutical drug classes to determine best outcomes for prescription drug treatment.
Study: NCT06033651

Intervention type: RADIATION
Intervention: x-ray
Description: A sample of blood will be taken and sent to a lab in Surrey to check for metal ions.
Study: NCT06099847

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS Stimulation
Description: Sacral TENS device without appropriate electrical stimulation have been applied to directly the skin of sacral area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral TENS Stimulation
Description: Sacral TENS stimulation have been applied to directly the skin of sacral area.
Study: NCT06268275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp block
Description: Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Receive Intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application
Study: NCT04690023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerves group (PENG) block
Description: Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-inguinal fascia-iliaca compartment block
Description: Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,75% in PENG block
Description: 20 ml injection of ropivacaine 0,75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,375% in SFICB block
Description: 40 ml injection of ropivacaine 0,375%
Study: NCT05831813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Based Cognitive Behavioural Intervention
Description: A goal-based cognitive behavioural intervention in a group format that addresses negative social cognitions and focuses on social approach processes
Study: NCT06346860

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Regional Block Comparison
Description: Comparing postoperative pain and opioid consumption in groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block Comparison
Description: Comparing postoperative pain and opioid consumption in groups
Study: NCT06305728

Intervention type: DIAGNOSTIC_TEST
Intervention: 89Zr-DFO-HuMab-5B1 immunoPET
Description: Participants who choose to will undergo immunoPET before surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: HP MRI
Description: Participants who choose to will undergo HP MRI before surgery.

Intervention type: COMBINATION_PRODUCT
Intervention: Blood assay
Description: Will be drawn within 6 weeks of surgery and annually as post operative care
Study: NCT04978675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 rhPSMA-7.3
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study: NCT05929482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infección de Amor (Infectious Love)
Description: Infectious Love is a filmed dramatized story (telenovela/soap opera) culturally tailored for US Latinas and delivered online.~IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location.
Study: NCT06176339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline Oral Tablet
Description: Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
Study: NCT05061784

Intervention type: PROCEDURE
Intervention: Routine thymectomy, which has been performed
Description: There is no intervention
Study: NCT05760053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP/EC+PD-1
Description: Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
Study: NCT06018181

Intervention type: DRUG
Intervention: Shuxuetong Injection
Description: According to clinical real treatment records
Study: NCT04652167

Intervention type: DIAGNOSTIC_TEST
Intervention: PCT
Description: Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration.

Intervention type: DIAGNOSTIC_TEST
Intervention: suPAR
Description: Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard care
Description: Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
Study: NCT05792969

Intervention type: BEHAVIORAL
Intervention: Functional measures and public health outcomes
Description: Questionnaires:~* Activities of daily living - ADL~* Barthel Index~* Instrumental activities of daily living- IADL~* Health Related Quality of Life - EQ-5D-5L~* Geriatric Depression Scale (GDS)~* State-Trait Anxiety Inventory - STAI-Y)~* Caregiver Burden Inventory questionnaire (CBI)

Intervention type: BEHAVIORAL
Intervention: Functional measures and public health outcomes
Description: Questionnaires:~* Activities of daily living - ADL~* Barthel Index~* Instrumental activities of daily living- IADL~* Health Related Quality of Life - EQ-5D-5L~* Geriatric Depression Scale (GDS)~* State-Trait Anxiety Inventory - STAI-Y)~* Caregiver Burden Inventory questionnaire (CBI)
Study: NCT05708625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Sodium stibogluconate
Description: Sessions will be held once weekly for a maximum of 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intralesional Cryotherapy
Description: Intralesional Cryotherapy. Sessions will be held every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Voriconazole
Description: Weekly intralesional Voriconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral doxycycline
Description: 200 mg daily for 6 weeks or till complete cure
Study: NCT06172881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: A soft contact lens that will be worn only at the study visit.
Study: NCT06015425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINDD STIM+
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study: NCT04089969

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTA/FFRct
Description: Computed Tomography Angiogram with Fractional Flow Reserve. A Ct scan of the heart's blood vessels.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SOC cardiovascular evaluation
Description: Standard of care (SOC) cardiovascular evaluation i.e ECG, 2 D echocardiogram and pharmacologic stress test such as Dobutamine and Myocardial Perfusion Imaging stress test.
Study: NCT05848557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mSaada
Description: mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
Study: NCT05572073

Intervention type: OTHER
Intervention: Natural History Study
Description: Natural History Study

Intervention type: OTHER
Intervention: Natural History Study
Description: Natural History Study
Study: NCT05685589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINDful TIME
Description: The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.